The CLIP1 – LTK fusion: anew oncogenic driver in non-small-cell lung cancer?

Future OncologyAhead of Print EditorialThe CLIP1–LTK fusion: A new oncogenic driver in non-small-cell lung cancer?Rebecca Ibrahim, Claude Chahine, Tony Felefly, Nadine Khalife & Khalil SalehRebecca IbrahimInternational Department, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author, Claude ChahineInternational Department, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author, Tony FeleflyRadiation Oncology Department, Saint-Joseph University, Beyrouth, 1100, LebanonSearch for more papers by this author, Nadine KhalifeDepartment of Head & Neck Oncology, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this author & Khalil Saleh *Author for correspondence: Tel.: +33 142 114 211; E-mail Address: khalil_saleh@live.comhttps://orcid.org/0000-0002-2985-2202International Department, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceSearch for more papers by this authorPublished Online:21 Mar 2023https://doi.org/10.2217/fon-2022-1232AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: ALK fusionCLIP1-LTK fusionlorlatinibnon-small-cell lung cancertyrosine kinase inhibitorsReferences1. Guo H, Zhang J, Qin C et al. Biomarker-targeted therapies in non-small cell lung cancer: current status and perspectives. Cells 11(20), 3200 (2022).Crossref, Medline, CAS, Google Scholar2. Howlader N, Forjaz G, Mooradian MJ et al. The effect of advances in lung-cancer treatment on population mortality. N. Engl. J. Med. 383(7), 640–649 (2020).Crossref, Medline, CAS, Google Scholar3. Soria J-C, Ohe Y, Vansteenkiste J et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378(2), 113–125 (2018).Crossref, Medline, CAS, Google Scholar4. Kwak EL, Bang Y-J, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363(18), 1693–1703 (2010).Crossref, Medline, CAS, Google Scholar5. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949–954 (2002).Crossref, Medline, CAS, Google Scholar6. Paik PK, Drilon A, Fan P-D et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 5(8), 842–849 (2015).Crossref, Medline, CAS, Google Scholar7. Farago AF, Taylor MS, Doebele RC et al. Clinicopathologic features of non-small-cell lung cancer harboring an NTRK gene fusion. JCO Precis. Oncol. 2018, PO.18.00037 (2018).Medline, Google Scholar8. Tsuta K, Kohno T, Yoshida A et al. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis. Br. J. Cancer 110(6), 1571–1578 (2014).Crossref, Medline, CAS, Google Scholar9. Gautschi O, Milia J, Filleron T et al. Targeting RET in patients with RET-rearranged lung cancers: results from the Global, Multicenter RET Registry. J. Clin. Oncol. 35(13), 1403–1410 (2017).Crossref, Medline, CAS, Google Scholar10. Kim HR, Lim SM, Kim HJ et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann. Oncol. 24(9), 2364–2370 (2013).Crossref, Medline, CAS, Google Scholar11. Chevallier M, Borgeaud M, Addeo A, Friedlaender A. Oncogenic driver mutations in non-small cell lung cancer: past, present and future. World J. Clin. Oncol. 12(4), 217–237 (2021).Crossref, Medline, Google Scholar12. Izumi H, Matsumoto S, Liu J et al. The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer. Nature 600(7888), 319–323 (2021).Crossref, Medline, CAS, Google Scholar13. Roll JD, Reuther GW. ALK-activating homologous mutations in LTK induce cellular transformation. PLOS ONE 7(2), e31733 (2012).Crossref, Medline, CAS, Google Scholar14. Ben-Neriah Y, Bauskin AR. Leukocytes express a novel gene encoding a putative transmembrane protein-kinase devoid of an extracellular domain. Nature 333(6174), 672–676 (1988).Crossref, Medline, CAS, Google Scholar15. Kozutsumi H, Toyoshima H, Hagiwara K et al. Identification of the human ltk gene product in placenta and hematopoietic cell lines. Biochem. Biophys. Res. Commun. 190(2), 674–679 (1993).Crossref, Medline, CAS, Google Scholar16. Bernards A, de la Monte SM. The ltk receptor tyrosine kinase is expressed in pre-B lymphocytes and cerebral neurons and uses a non-AUG translational initiator. EMBO J. 9(7), 2279–2287 (1990).Crossref, Medline, CAS, Google Scholar17. Müller-Tidow C, Schwäble J, Steffen B et al. High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin. Cancer Res. 10(4), 1241–1249 (2004).Crossref, Medline, CAS, Google Scholar18. Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J. Thorac. Oncol. 12(11), 1611–1625 (2017).Crossref, Medline, Google Scholar19. Toyokawa G, Seto T. Updated evidence on the mechanisms of resistance to ALK Inhibitors and strategies to overcome such resistance: clinical and preclinical data. Oncol. Res. Treat. 38(6), 291–298 (2015).Crossref, Medline, CAS, Google Scholar20. Robert NJ, Nwokeji ED, Espirito JL et al. Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices. J. Clin. Oncol. 39(Suppl. 15), 9004–9004 (2021).Crossref, Google ScholarFiguresReferencesRelatedDetails Ahead of Print eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 19 times History Received 7 December 2022 Accepted 25 January 2023 Published online 21 March 2023 Information© 2023 Future Medicine LtdKeywordsALK fusionCLIP1-LTK fusionlorlatinibnon-small-cell lung cancertyrosine kinase inhibitorsFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download